Travere Therapeutics Inc (TVTX) Stock: A Review of the Recent Movement

In the past week, TVTX stock has gone down by -7.79%, with a monthly decline of -14.77% and a quarterly plunge of -26.99%. The volatility ratio for the week is 7.52%, and the volatility levels for the last 30 days are 6.45% for Travere Therapeutics Inc. The simple moving average for the past 20 days is -10.69% for TVTX’s stock, with a -32.10% simple moving average for the past 200 days.

Is It Worth Investing in Travere Therapeutics Inc (NASDAQ: TVTX) Right Now?

The 36-month beta value for TVTX is at 0.62. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for TVTX is 75.03M, and currently, shorts hold a 13.42% of that float. The average trading volume for TVTX on April 04, 2024 was 1.23M shares.

TVTX) stock’s latest price update

The stock price of Travere Therapeutics Inc (NASDAQ: TVTX) has dropped by -0.85 compared to previous close of 7.04. Despite this, the company has seen a fall of -7.79% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-03 that SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present nine abstracts in rare kidney disease at the World Congress of Nephrology (WCN) in Buenos Aires, Argentina, on April 13-16, 2024, and the American Nephrology Nurses Association (ANNA) National Symposium in Orlando, Florida, on April 14-17, 2024. At WCN, the Company will present subgroup analyses of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) showing the treatment effect across participants with different levels of baseline proteinuria.

Analysts’ Opinion of TVTX

Citigroup, on the other hand, stated in their research note that they expect to see TVTX reach a price target of $10, previously predicting the price at $7. The rating they have provided for TVTX stocks is “Buy” according to the report published on December 05th, 2023.

Citigroup gave a rating of “Neutral” to TVTX, setting the target price at $7 in the report published on November 20th of the previous year.

TVTX Trading at -14.74% from the 50-Day Moving Average

After a stumble in the market that brought TVTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.88% of loss for the given period.

Volatility was left at 6.45%, however, over the last 30 days, the volatility rate increased by 7.52%, as shares sank -13.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.13% lower at present.

During the last 5 trading sessions, TVTX fell by -7.79%, which changed the moving average for the period of 200-days by -59.42% in comparison to the 20-day moving average, which settled at $7.76. In addition, Travere Therapeutics Inc saw -22.36% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TVTX starting from Dube Eric M, who sale 19,122 shares at the price of $8.70 back on Feb 01 ’24. After this action, Dube Eric M now owns 350,600 shares of Travere Therapeutics Inc, valued at $166,435 using the latest closing price.

REED ELIZABETH E, the SVP, GC & CORPORATE SECRETARY of Travere Therapeutics Inc, sale 4,764 shares at $8.71 during a trade that took place back on Feb 01 ’24, which means that REED ELIZABETH E is holding 76,270 shares at $41,495 based on the most recent closing price.

Stock Fundamentals for TVTX

Current profitability levels for the company are sitting at:

  • -1.71 for the present operating margin
  • 0.88 for the gross margin

The net margin for Travere Therapeutics Inc stands at -0.56. The total capital return value is set at -0.56. Equity return is now at value -287.12, with -47.87 for asset returns.

Based on Travere Therapeutics Inc (TVTX), the company’s capital structure generated 0.66 points at debt to capital in total, while cash flow to debt ratio is standing at -0.73. The debt to equity ratio resting at 1.9. The interest coverage ratio of the stock is -58.1.

Currently, EBITDA for the company is -331.81 million with net debt to EBITDA at -1.18. When we switch over and look at the enterprise to sales, we see a ratio of 4.41. The receivables turnover for the company is 9.39for trailing twelve months and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.47.


In conclusion, Travere Therapeutics Inc (TVTX) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts